Dafinchi
Insulet's Growth Strategy Amid Market Challenges Q1 2026
Insulet outlines its strategic approach to maintaining market leadership in the AID category despite macroeconomic headwinds and rising costs for Q1 2026.
Read post
Detailed company information
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 06, 2026
Earnings Transcript for 2025 - Q4Released: Feb 18, 2026
Earnings Transcript for 2025 - Q3Released: Nov 06, 2025
Earnings Transcript for 2025 - Q2Released: Aug 07, 2025
Earnings Transcript for 2025 - Q1Released: May 08, 2025
Earnings Transcript for 2024 - Q4Released: Feb 20, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 09, 2024
Earnings Transcript for 2023 - Q4Released: Feb 22, 2024
Earnings Transcript for 2023 - Q3Released: Nov 02, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 04, 2023
Earnings Transcript for 2022 - Q4Released: Feb 23, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 07, 2022
Earnings Transcript for 2022 - Q1Released: May 06, 2022
Earnings Transcript for 2021 - Q4Released: Feb 23, 2022
Earnings Transcript for 2021 - Q3Released: Nov 04, 2021
Earnings Transcript for 2021 - Q2Released: Aug 06, 2021
Earnings Transcript for 2021 - Q1Released: May 07, 2021
Earnings Transcript for 2020 - Q4Released: Feb 23, 2021
Earnings Transcript for 2020 - Q3Released: Nov 04, 2020
SENS Senseonics Holdings, Inc.
Insulet outlines its strategic approach to maintaining market leadership in the AID category despite macroeconomic headwinds and rising costs for Q1 2026.
Read postInsulet emphasizes its commitment to maintaining market leadership in the AID category for Q1 2026 through technological innovation and category expansion strategies.
Read post